Novexel SA and Forest Laboratories Holdings Ltd., a wholly owned subsidiary of Forest Laboratories Inc. signed an agreement allowing the U.S. company to develop, manufacture and commercialize Novexel's novel intravenous beta lactamase inhibitor, NXL104, in combination with Forest's ceftaroline. (BioWorld International)

Privately held CoGenesys Inc., a 2006 spinout of Human Genome Sciences Inc., is being acquired by potential collaborator Teva Pharmaceutical Industries Ltd. in a $400 million cash deal. (BioWorld Today)